Niraparib for the treatment of metastatic NSCLC in a patient with BRCA2 germinal mutation: a case report
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Niraparib for the treatment of metastatic NSCLC in a patient with BRCA2 germinal mutation: a case report
Authors
Keywords
-
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-29
DOI
10.1016/j.cllc.2023.10.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Case report: olaparib use in metastatic lung adenocarcinoma withBRCA2pathogenic variant
- (2023) Jonathan Soon Jian Hao et al. Cold Spring Harbor Molecular Case Studies
- Mechanism of PARP inhibitor resistance and potential overcoming strategies
- (2023) Xiaoyu Fu et al. Genes and Diseases
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2
- (2023) Dwight H. Owen et al. JOURNAL OF CLINICAL ONCOLOGY
- Homologous Recombination Deficiency: Concepts, Definitions, and Assays
- (2022) Mark D Stewart et al. ONCOLOGIST
- Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis
- (2022) Chang’e Jin et al. ANTI-CANCER DRUGS
- Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
- (2022) Yonina R. Murciano-Goroff et al. Nature Communications
- A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficient Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400G)
- (2021) Taofeek K. Owonikoko et al. Clinical Lung Cancer
- Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification
- (2021) Lin Zhong et al. Annals of Diagnostic Pathology
- Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report
- (2021) Thomas Waddington et al. Clinical Lung Cancer
- A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
- (2021) Jonathan W. Riess et al. JOURNAL OF CLINICAL ONCOLOGY
- Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
- (2021) Li Zhang et al. World Journal of Clinical Cases
- A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
- (2021) Miklos Diossy et al. npj Precision Oncology
- ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium
- (2020) Giovanni Rossi et al. EXPERT OPINION ON PHARMACOTHERAPY
- A prospective phase II single arm study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: Rationale and Study design
- (2020) Francesco Passiglia et al. Clinical Lung Cancer
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
- (2020) Maddison Rose et al. Frontiers in Cell and Developmental Biology
- BRCA1/2 germline mutations and response to PARP inhibitor treatment in lung cancer.
- (2019) Wenfeng Fang et al. JOURNAL OF CLINICAL ONCOLOGY
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors
- (2019) Wenchao Ji et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started